Compare Recursion Pharmaceuticals Inc (RXRX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Waste Management, Inc. trades at $217.2 (market cap $86.51B). The key difference: Waste Management, Inc. is far larger — about 49.7× Recursion Pharmaceuticals Inc's market cap, and Waste Management, Inc. pays a 1.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WM | |
|---|---|---|
Market Cap | $1.74B | $86.51B |
Sector | Health | Industrials |
52-Week High | $6.79 | $246.51 |
52-Week Low | $2.84 | $196.77 |
Enterprise Value | $1.26B | $109.31B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
WM trades at $217.78, down 0.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, beating EPS estimates at $2.02 versus $1.98 expected, but missed Q4 2025. Revenue grew to $25.20B in 2025, with a net income margin of 11.12%. Recent news highlights CEO transition and strong institutional buying, including a 26,113.1% position increase by California State Teachers Retirement System in Q2 2026.
Outlook remains positive with a consensus price target of $263.43, implying 21% upside, supported by steady waste demand and sustainability investments. Risks include high debt levels, with a debt-to-asset ratio of 49.97% in 2025, and valuation concerns at a P/E of 30.8. The stock offers a dividend yield from recent payouts, but investors face execution risks amid leadership changes and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
